## **PATENT**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Wadih ARAP

Reanata PASQUALINI

Serial No.: 10/784,537

Filed: February 23, 2004

For: AMINOPEPTIDASE A (APA)

TARGETING PEPTIDES FOR THE

TREATMENT OF CANCER

Group Art Unit: 1648

Examiner: Li, Bao Q.

Atty. Dkt. No.: UTSC:872US

Confirmation No.: 2636

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the patent electronically filed with the United States Patent and Trademark Office via EFS-Web on the patent electronic states and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the United States and the United States are stated in the Unite

November 20, 2007

Date

ven L. Highlander

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:872US.

Applicants respectfully request that the listed documents be made of record in the present case.

Speen L. H. Con-Parker Re. No 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

November 20, 2007